Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund

Executive Summary

Two of the three companies vying for an additional share of England’s CDK4/6 inhibitor market have now secured reimbursement for the use of their products in combination with fulvestrant for advanced breast cancer.

You may also be interested in...



Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund

Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.

SMC Follows NICE And Backs Lilly’s Verzenios In Advanced Breast Cancer

The SMC has given the all clear to funding for Lilly’s Verzenios for breast cancer, Richter’s Reagila for schizophrenia, and MSD’s Keytruda for melanoma. However, it rejected Alliance’s Xonvea for sickness in pregnancy because the evidence on benefits and cost effectiveness did not stack up.

Blow For Novartis As England’s NICE Says No To Kisqali

Novartis is having a harder time than Eli Lilly at getting health technology assessment body NICE to agree to make its breast cancer CDK4/6 inhibitor in combination with fulvestrant available on the National Health Service.

Topics

Related Companies

UsernamePublicRestriction

Register

PS140517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel